No insider has reported a holding in the last two years, so insiders are counted in "Everyone else".
None.
None.
No insider has filed a notice of proposed sale (Form 144) for Omega Therapeutics, Inc. in the last 12 months.
| Holder | Shares | % of company | Change vs last qtr | 8 quarters | Held since | % of their book |
|---|---|---|---|---|---|---|
|
HN
Huntington National Bank
|
1 | 0.00% | Unchanged | 2023 | 0.0% | |
|
Shares held by quarter
Peak holding1 (Q3'24)
Change over 8 quarters0
Share of the company0.000%
|
||||||
| Fund | Position value | Shares | % of company | % of the fund | As of |
|---|---|---|---|---|---|
|
VT
Vanguard Index Funds
|
$581K | 779.1K | 1.41% | 0.00% | December 31, 2024 |
|
VE
Vanguard Index Funds
|
$231K | 309.9K | 0.56% | 0.00% | December 31, 2024 |
6 more funds behind a free account
See every fund holding Omega Therapeutics, Inc. and how much of the fund the position is.
Sign up free| Holder | Shares | % of company | Change vs last qtr | 8 quarters | Held since | % of their book |
|---|---|---|---|---|---|---|
|
NA
Noubar Afeyan
5%+ holder
13D · 52.8%
|
29.2M | 52.79% | — | — |
— | — |
|
This holder reports through Schedule 13D/G, not a quarterly 13F.
|
||||||
|
FP
Flagship Pioneering, Inc.
5%+ holder
13D · 40.2%
|
22.2M | 40.17% | — | — |
— | — |
|
This holder reports through Schedule 13D/G, not a quarterly 13F.
|
||||||
15 more holders behind a free account
See every insider and 5%+ holder of Omega Therapeutics, Inc..
Sign up freeLoading...